Abstract: The invention relates to a composition comprising melatonin, a metabolite or derivative thereof and coenzyme Q10 and to use thereof for the production of a pharmaceutical or cosmetic composition for the treatment of the skin, said composition potentiating the movement of both molecules into the mitochondrion and facilitating percutaneous absorption, in which both the melatonin and the CoQ10 can reach all of the strata of the skin.

Abstract: Use of simple acyclic polyamines for the treatment of parasites of the family Trypanosomatidae The present invention provides the use of certain single acyclic polyamines of Formula (I), attached to heterocycles, for the treatment of leishmaniasis and trypanosomiasis. All the compounds studied show antiparasitic activity against Leishmania species, comparable or superior to that of the active ingredient of the drug commonly used to treat this disease, but with a macrophage toxicity similar to or, in most cases, lower than that of the commercial reference compound, and with higher selectivity indices against strains representative of the three clinical forms of the disease: cutaneous, mucocutaneous and visceral. The compounds show ability to inhibit parasite superoxide dismutase, generally at concentrations lower than those required to inhibit human superoxide dismutase. All this supports its usefulness for treating leishmaniasis and also trypanosomiasis.

Abstract: The present invention relates to a new family of titanium heterometallic structured metal-organic materials (MOFs) having, among other characteristics, high porosity, stability in an aqueous medium and photocatalytic activity under visible light and UV radiation. The new family of materials has a structural unit that combines tetravalent titanium with multiple combinations of divalent metals with a homogeneous distribution at atomic level in the MOF structure. The invention also relates to methods for obtaining them with high yields, in addition to their uses in the generation of solar fuels, photoactivated degradation, photoreduction of CO2, heterogeneous catalysis, as a component or part of an electronic component and/or as a porous or photoactive coating for controlling pollutants, inter alia.

Abstract: The invention relates to a composition comprising melatonin, a metabolite or derivative thereof and coenzyme Q10 and to use thereof for the production of a pharmaceutical or cosmetic composition for the treatment of the skin, said composition potentiating the movement of both molecules into the mitochondrion and facilitating percutaneous absorption, in which both the melatonin and the CoQ10 can reach all of the strata of the skin.

Abstract: The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.

Abstract: The present invention provides a method for identifying epithelial cells circulating in peripheral blood, which allows individuals who suffer from a disease that presents with epithelial cell destruction to be discriminated from those who do not. The invention also relates to a kit or device for carrying out the methods of the invention.

Abstract: The present invention relates to the use of melatonin for the preparation of a pharmaceutical composition suitable for intratumoral administration for the treatment of tumors. This composition comprises high concentrations of melatonin, melatonin derivatives or metabolites, such that melatonin exerts an oxidizing effect, increasing the production of free radicals and activating cell death.

Abstract: The present invention relates to a composition, preferably an aqueous pharmaceutical solution, comprising a water-soluble polymer derived from cellulose and hyaluronic acid, preferably comprising carboxymethylcellulose and hyaluronic acid. More specifically, the invention relates to a composition, preferably an aqueous pharmaceutical solution, comprising 0.0001%-5% hyaluronic acid and 0.005%-2% carboxymethylcellulose. The invention also relates to the use of said composition, preferably an aqueous pharmaceutical solution, in the manufacturing of a medicament for the treatment of lesions in the mucosa by means of endoscopic resection, for example, the resection of polyps and/or tumors of the gastrointestinal mucosa.

Abstract: The invention relates to the use of microorganisms as plant growth stimulants and for the biological control of bacteria, insects, fungi and phytopathogenic nematodes. More specifically, the invention relates to the use of microorganisms of the genus Bacillus, more specifically the Bacillus methylotrophicus species, as well as to cultures thereof, compositions comprising these bacteria, different culture methods and the products comprising same, as plant growth stimulants and for the biological control of bacteria, insects, fungi and phytopathogenic nematodes.

Abstract: The present invention is encompassed in the field of biomedicine and more specifically tissue engineering. It relates specifically to an in vitro method for preparing an artificial tissue, to the artificial tissue obtainable by said method and to the use of this artificial tissue to partially or completely increase, restore or replace the functional activity of a damaged tissue or organ.

Abstract: Related are a chemical warfare agent (CWA) decontaminant, a method of decontaminating a CWA using the CWA decontaminant, and a product including the CWA decontaminant. The CWA decontaminant may include a metal-organic framework (MOF) including at least one metallic compound among metal hydroxide, metal hydride, metal acetate, metal methoxide, and metal oxide, and the at least one metallic compound may be dispersed either on a surface of the MOF or in pores of the MOF, or both.

Abstract: The invention relates to a composition comprising melatonin, a metabolite or derivative thereof and coenzyme Q10 and to use thereof for the production of a pharmaceutical or cosmetic composition for the treatment of the skin, said composition potentiating the movement of both molecules into the mitochondrion and facilitating percutaneous absorption, in which both the melatonin and the CoQ10 can reach all of the strata of the skin.

Abstract: The invention relates to a composition comprising melatonin, a metabolite or derivative thereof and coenzyme Q10 and to use thereof for the production of a pharmaceutical or cosmetic composition for the treatment of the skin, said composition potentiating the movement of both molecules into the mitochondrion and facilitating percutaneous absorption, in which both the melatonin and the CoQ10 can reach all of the strata of the skin.

Abstract: The present invention relates to a serum-free conditioned medium that solves the drawbacks mentioned in the prior art, as it does not require prior handling of the cells, and it furthermore allows starting from a large population with no additional cost. This medium favors in vitro proliferation and conservation of the pluripotency potential that allows maintaining a state that is undifferentiated with respect to the subpopulation of cancer stem cells (CSCs) and in turn does not allow survival of the differentiated cells.

Abstract: Disclosed are small ncRNAs that may be used as biomarkers for classifying the health status of an individual. The disclosure also provides screening methods for identifying ncRNA biomarkers.

Abstract: The invention relates to a composition comprising melatonin, a metabolite or derivative thereof and coenzyme Q10 and to use thereof for the production of a pharmaceutical or cosmetic composition for the treatment of the skin, said composition potentiating the movement of both molecules into the mitochondrion and facilitating percutaneous absorption, in which both the melatonin and the CoQ10 can reach all of the strata of the skin.

Abstract: The invention relates to a memory cell consisting of an isolated MOS transistor having a drain (8), a source (7) and a body region covered with an insulated gate (12), in which the body region is divided through its thickness into two separate regions (13, 14) of opposite conductivity types extending parallel to the plane of the gate, the body region closest to the gate having the opposite conductivity type to that of the drain/source.

Abstract: A memory cell formed of a semiconductor nanorod having its ends heavily doped to form source and drain regions and having its central portion including, between the source and drain regions, an N-type region surrounded on a majority of its periphery with a quasi-intrinsic P-type region, and wherein the P-type region itself is surrounded with an insulated gate.

Abstract: The present invention relates to the use of a composition comprising melatonin or a derivative thereof at a proportion of 2.5% to 5% w/v for preparing a pharmaceutical composition for treating and/or preventing mucositis. The mucositis is preferably caused by radiotherapy and/or chemotherapy and preferably refers to oral mucositis.

Abstract: A memory cell formed of a semiconductor nanorod having its ends heavily doped to form source and drain regions and having its central portion comprising, between the source and drain regions, an N-type region surrounded on a majority of its periphery with a quasi-intrinsic P-type region, and wherein the P-type region itself is surrounded with an insulated gate.